Kirkland, Wash. – October 27, 2026 -- EIT Pharma has appointed Dr. Joseph Toerner, a 26-year veteran of the U.S. Food and Drug Administration (FDA), as Chief Medical Officer, effective immediately, while its lead hepatitis D candidate lonafarnib is under regulatory review.

Chanhassen – October 27, 2026 -- Every patient with investigator-assessed clinical deterioration in an exploratory 15-patient glioblastoma analysis showed sustained increases in lactate dehydrogenase (LDH) during treatment, Alpheus Medical, Inc. reported at the ESMO Congress 2026 in Madrid.

New York – October 27, 2026 -- ProJenX will present long-term Phase 1b data at the 2026 NEALS Annual Meeting showing that its ALS candidate prosetin reached target therapeutic exposures and kept a favorable safety profile over extended dosing. The meeting runs Oct. 27-30 in Clearwater, Florida, and online.

San Diego – October 27, 2026 -- Atrium Therapeutics (Nasdaq: RNA) has dosed the first patient in Corventis, a Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome, and expects initial proof-of-concept data in the second half of 2027.

WASHINGTON – October 27, 2026 -- Vanda Pharmaceuticals (Nasdaq: VNDA) reported that NEREUS (tradipitant) cut the incidence of semaglutide-induced vomiting by 27% in a Phase III trial. Vomiting occurred in 43.0% of treated participants (61/142) versus 58.5% on placebo (96/164), with a p-value of 0.006.

The company plans to discuss the data with the U.S. Food and Drug Administration (FDA). It intends to file a supplemental New Drug Application (sNDA) for preventing vomiting associated with GLP-1 receptor agonist therapy.

Cambridge, Mass. – October 27, 2026 -- CREATE Medicines will present preclinical data showing complete B cell depletion in lymph nodes, spleen and bone marrow after low doses of its in vivo CAR-T therapy at the APLAR 2026 Congress in Seoul, running October 28 to November 1 at the COEX Convention & Exhibition Center.

INDIANAPOLIS – October 27, 2026 -- Carnyx Therapeutics has advanced its lead oral sleep candidate, CNYX-005, into Investigational New Drug (IND)-enabling development, bringing the preclinical asset closer to potential first-in-human studies.

Global – October 27, 2026 -- Solid Biosciences has dosed the first participant in FALCON, a Phase 1b trial of SGT-212, its investigational gene therapy for Friedreich's ataxia (FA), and expects to release an initial data update in the second half of 2026, subject to patient enrollment.

SHANGHAI – October 27, 2026 -- Henlius' serplulimab combined with chemotherapy delivered a median overall survival (OS) of 12.4 months versus 10.2 months for atezolizumab plus chemotherapy in the U.S. ASTRIDE study of first-line extensive-stage small cell lung cancer (ES-SCLC). The company presented the data at the European Society for Medical Oncology (ESMO) Congress 2026.

STOCKHOLM – October 27, 2026 -- Sobi raised its 2026 revenue growth guidance to high-teens to low-20s per cent at constant exchange rates (CER), up from mid- to high-teens, after third-quarter revenue grew 16 per cent at CER to SEK 9,124 M (7,776). Reported growth was 17 per cent, and year-to-date growth stands at 23 per cent at CER. The company also announced that CEO Guido Oelkers will step down no later than the end of January 2027.